Patent · US Active

Double-stranded ribonucleic acid with increased effectiveness in an organism

US7786290B2 · kind B2 · utility

92Cited by

1References

31Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Claudia Woppmann · Bayreuth, DE
Hans-Peter Vornlocher · Bayreuth, DE
Philipp Hadwiger · Kulmbach, DE
Matthias John · Hallstadt, DE
Stefan Limmer · Neudrossenfeld, DE

Key dates

Filing date	Jun 14, 2004
Grant date	Aug 31, 2010
Priority date	—
Expiry date	Aug 19, 2026

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2330/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a method for the targeted selection of a double-stranded ribonucleic acid (dsRNA) consisting of two single strands that exhibits increased effectiveness in inhibiting the expression of a target gene by means of RNA interference, wherein at least end of the dsRNA comprises a nucleotide overhang of 1 to 4 unpaired nucleotides in length; wherein the unpaired nucleotide adjacent to the terminal nucleotide pair comprises a purine base; and wherein the terminal nucleotide pair on both ends of the dsRNA is a G-C pair, or at least two of the last four consecutive terminal nucleotide pairs are G-C pairs.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.